Altasciences Featured Audio

  1. Issue 27: The Complexities Of Early Phase Ophthalmic Drug Development 2/8/2023

    Drug development in the ocular space has specific challenges. Explore how an end-to-end solution can facilitate a path to Phase 2.

  2. Issue 25: Flexibility In Phase I Study Timing 2/8/2023

    Discover how having early access to trial results and data can help to make inform decisions later in the development journey, support funding opportunities, and help solidify plans around sound data.

  3. Issue 24: Shortening Drug Development Timelines With Asian Ethnobridging Trials 2/8/2023

    Discover how local ethnobridging studies during Phase I can reduce drug development timelines by the number of years typically needed to complete clinical development in a target region.

  4. Getting A Vaccine To Market: The Timeline, The Process, And What To Expect 2/8/2023

    Dr. Beatrice Setnik, Chief Scientific Officer at Altasciences, discusses the drug and vaccine development process to provide insight on the typical timelines for getting a vaccine to market.

  5. Building Your Early Phase Clinical Trial Data, From Protocol To Regulatory Submission 2/7/2023

    Learn about best practices and approaches in Phase I clinical trials, from conceptualization and initial protocol development, collection and analysis, through final regulatory submission.

  6. Issue 19: Psychedelics And Entactogens 2/3/2023

    Schedule I, or Class I (CI) drugs are currently restricted to research in the U.S. Explore the challenges associated with Schedule I therapeutic development.

  7. Issue 18: Planning Your First-In-Human Trial 2/3/2023

    A first-in-human clinical trial is a significant milestone in the development of a potential new drug. Listen and learn how to plan your first in-human clinical trial.

  8. Issue 14 — CNS Active Drugs: Complex Considerations 2/2/2023

    In this issue, review complex considerations for the development of central nervous system-active drugs, including the Controlled Substances Act, preclinical and clinical data requirements, and additional assessments your program may need.

  9. Issue 10: Tackling Early Phase Development Challenges With Effective First-In-Human Studies 2/2/2023

    First-in-human (FIH) trials in the early phases of drug development represent a critical milestone in the approval of medicines.

  10. Issue 9: Cardiac Safety Assessment In Clinical Trials 2/2/2023

    Listen to this discussion on global regulations, design, and timing of QT assessment, including a case study from a first-in-human clinical trial.